Clinical Trials Logo

Clinical Trial Summary

This study will determine the neurological profile and predictors of outcomes in patients with COVID-19 disease in the Philippines. It will also evaluate if there is significant difference between COVID-19 patients with neurological manifestations compared to those COVID-19 patients without neurological manifestations in terms of various prespecified clinical outcomes. Furthermore, the likelihood of these outcomes in COVID-19 patients with neurological manifestations compared to those without neurological manifestation will be determined in this study.


Clinical Trial Description

This quantitative, retrospective, cohort study will determine the following: 1) demographic, clinical and neurological profile of patients with COVID-19 disease in the Philippines; 2) the frequency of neurological symptoms and new-onset neurological disorders/complications in patients with COVID-19 disease; 3) the neurological manifestations that are significant predictors of mortality, respiratory failure, duration of ventilator dependence, intensive care unit (ICU) admission, length of ICU stay, and length of hospital stay; 4) if there is significant difference between COVID-19 patients with neurological manifestations compared to those COVID-19 patients without neurological manifestations in terms of mortality, respiratory failure, duration of ventilator dependence, ICU admission, length of ICU stay and length of hospital stay; and 5) the likelihood of mortality, respiratory failure and ICU admission in COVID-19 patients with neurological manifestations compared to those without neurological manifestations. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04386083
Study type Observational
Source University of the Philippines
Contact Adrian I Espiritu, MD
Phone +639258520341
Email aiespiritu@up.edu.ph
Status Recruiting
Phase
Start date June 10, 2020
Completion date March 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05091411 - Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells) Phase 3
Completed NCT05107375 - Clinical Study of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell) Combined With Influenza Vaccine Phase 3
Active, not recruiting NCT05128643 - Clinical Study on the Immune Program of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell) Phase 3
Completed NCT04988217 - Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19) Phase 1/Phase 2
Completed NCT04579393 - Fostamatinib for Hospitalized Adults With COVID-19 Phase 2
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Completed NCT04646044 - A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 Phase 1
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT05092568 - Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
Completed NCT05364268 - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
Completed NCT06189040 - Immunogenicity After COVID-19 Vaccines in Adapted Schedules Phase 4
Recruiting NCT04401436 - COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Not yet recruiting NCT04395742 - 1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
Recruiting NCT04388631 - Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
Completed NCT05501288 - Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019 N/A
Active, not recruiting NCT05216471 - Identify Coronavirus Disease by Chest X-ray
Terminated NCT04672564 - Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients Phase 3
Completed NCT04967781 - Autoimmunity Contributes to the Severe Progression of COVID-19
Completed NCT04678830 - Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19 Phase 2